Highlights of This Issue 4731

SPECIAL FEATURES

CCR Translations

4733  Prostate Cancer SubtyPINg BiomarkKers and Outcome: Is Clarity EmERGing?
Steven C. Smith and Scott A. Tomlins
See related article, p. 4904

4737  Twisting and Ironing: Doxorubicin Cardiotoxicity by Mitochondrial DNA Damage
Karin C. Nitis and John L. Nitis
See related article, p. 4873

Molecular Pathways

4740  Molecular Pathways: Targeting RAC–p21-Activated Serine–Threonine Kinase Signaling in RAS-Driven Cancers
Nicole M. Baker, Hoi Yee Chow, Jonathan Chernoff, and Channing J. Der

CANCER THERAPY: CLINICAL

4747  Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGF1 and IGFII, in Patients with Advanced Solid Tumors
Paul Haluska, Michael Menefee, Elizabeth R. Plimack, Jonathan Rosenberg, Donald Northfelt, Theresa LaVallee, Li Shi, Xiang-Qing Yu, Patricia Burke, Jaiqi Huang, Jaye Viner, Jennifer McDevitt, and Patricia LoRusso

4758  Is the “3+3” Dose-Escalation Phase I Clinical Trial Design Suitable for Therapeutic Cancer Vaccine Development? A Recommendation for Alternative Design
Osama E. Rahma, Emily Gammoh, Richard M. Simon, and Samir N. Khleif

4768  The Role of Age on Dose-Limiting Toxicities in Phase I Dose-Escalation Trials

4776  Phase I Study of RGB-286638, A Novel, Multitargeted Cyclin-Dependent Kinase Inhibitor in Patients with Solid Tumors
Diane A.J. van der Bijssen, Herman Burger, Peter de Bruijn, Cor H.J. Lamers, Nicole Naus, Hannes Loferer, Erik A.C. Wiemer, Ron H.J. Mathijssen, and Maja J.A. de Jonge

PERSONALIZED MEDICINE AND IMAGING

4784  A Three-microRNA Signature Predicts Responses to Platinum-Based Doublet Chemotherapy in Patients with Lung Adenocarcinoma
Motonobu Saito, Kouya Shiraishi, Kenji Matsumoto, Aaron J. Schetter, Hiroko Ogata-Kawata, Naoto Tsuchiya, Hideo Kunitoh, Hiroshi Nokihara, Shun-ichi Watanabe, Koji Tauta, Kensuke Kumamoto, Seiichi Takehoshi, Jun Yokota, Curtis C. Harris, and Takashi Kohn

4794  Clinical Significance of EpCAM mRNA-Positive Circulating Tumor Cells in Hepatocellular Carcinoma by an Optimized Negative Enrichment and qRT-PCR-Based Platform
Wei Guo, Xin-Rong Yang, Yun-Fan Sun, Min-Na Shen, Xiao-Lu Ma, Jiong Wu, Chun-Yan Zhang, Yan Zhou, Yang Xu, Bo Hu, Xin Zhang, Jian Zhou, and Jia Fan

4806  Monitoring Reversal of MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer Using 3'-Deoxy-3'-[18F]-Fluorothymidine Positron Emission Tomography
Francesca Iommelli, Viviana De Rosa, Sara Gargiulo, Mariarosaria Panico, Marcello Monti, Adelaide Greco, Matteo Gramanzini, Giovanni Ortosceco, Rosa Fonti, Arturo Brunetti, and Silvana Del Vecchio

4816  Functional Ex Vivo Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor Treatment
4962 Excess of Proximal Microsatellite-Stable Colorectal Cancer in African Americans from a Multiethnic Study

LETTERS TO THE EDITOR

4971 Androstenedione Is the Preferred Androgen Source in Hormone Refractory Prostate Cancer—Letter
Nima Sharifi and Richard J. Auchus

CORRECTION

4974 Correction: Prevalence and Clinical Implications of Epstein–Barr Virus Infection in De Novo Diffuse Large B-Cell Lymphoma in Western Countries

ABOUT THE COVER

The cover shows results from FISH analysis of prostate cancer cells with ERG rearrangement (top; loss of one green signal indicating translocation through deletion) and hemizygous PTEN deletion (bottom; loss of one red signal with preservation of green centromeric signals). For details, see the article by Khani and colleagues on page 4925 of this issue.
Clinical Cancer Research

20 (18)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/20/18

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.